Key takeaways
- Epithalon and epitalon are two spellings of one synthetic peptide, H-Ala-Glu-Asp-Gly-OH; FDA staff treat it as a different substance from epithalamin, the pineal-gland extract it was modelled on.
- FDA staff note that most pharmacological studies of epitalon come from one research group in Russia.
- FDA staff found three studies that gave it to people, none assessing safety, and concluded there are “no clinical data to support the safety” of epitalon in humans.
- FDA staff also raised a theoretical cancer concern linked to its reported effect on telomeres; HHS called CDER’s concerns “mechanistic rather than based on observed harm”.
- It is not an approved medicine in the US, UK, EU or Australia, and HHS named it in a draft, non-binding 2026 compounding policy that is not an approval.
01Epithalon at a glance
The short version, dated 18 November 2026. Every line is sourced at the end of the page.
| Question | Epithalon (epitalon) |
|---|---|
| What it is | A synthetic peptide of four amino acids, H-Ala-Glu-Asp-Gly-OH, 390.35 g/mol as the free base; an acetate salt also exists. |
| Other names | Epitalon, Ala-Glu-Asp-Gly, AEDG. Not the same substance as epithalamin, a cattle pineal-gland extract, according to FDA staff. |
| Evidence tier | T4 (cell) and T3 (animal). T2 for people: FDA staff found three studies, and the one they describe in detail measured a melatonin marker, not sleep or health outcomes. |
| Human studies | Three found by FDA staff, none assessing safety (2026). One registered study includes it in a skin serum, with no results (ClinicalTrials.gov, 18 Nov 2026). |
| United States | Not FDA-approved. In FDA’s compounding Category 2 from 29 Sep 2023 to 22 Apr 2026, now listed as a nomination withdrawn. Named in HHS’s draft compounding policy (30 Oct 2026), which is not binding and not an approval. |
| United Kingdom and EU | No approved product in the UK or seven other European countries, and none authorised by the European Medicines Agency (FDA’s 2026 review). |
| Australia | Not named in the Poisons Standard October 2026, and no group entry found that would cover it (text searched 18 Nov 2026). |
| WADA | Not named on the 2026 or 2027 List. We know of no government approval for it anywhere, so class S0, prohibited at all times, applies. |
02What is epithalon, and is it the same as epithalamin?
Epithalon, also written epitalon, is a peptide of four amino acids: alanine, glutamic acid, aspartic acid and glycine (Ala-Glu-Asp-Gly, or AEDG). FDA staff describe it as “a synthetic tetrapeptide derived from the amino acid composition” of epithalamin, an extract first obtained from the pineal glands of cattle. The pineal gland is the small gland in the brain that makes melatonin.
Epithalon is not epithalamin. FDA staff consider the two “different substances”: one is a defined peptide, the other a mix extracted from animal tissue. Studies of epithalamin are not studies of epitalon.
FDA staff also concluded that neither the free base nor the acetate salt is “well-characterized”, partly because the documents they reviewed lacked tests for impurities, aggregates and microbial quality. HHS later said lots from FDA-registered facilities now report the missing endotoxin, microbial and solvent results. Which form a vial holds can be checked only on a lab report for its own lot, and only if the report states it: how to read a COA. Sellers often call epitalon a “bioregulator”, a description rather than a legal category: see bioregulators.
03How has epithalon been studied, and in what models?
Cell and animal studies, and the human study FDA staff describe in detail. FDA staff note that most pharmacological studies come from Dr Vladimir Khavinson’s group in Russia.
Human cells, 2003 (T4). Khavinson’s group added epitalon to cultured human fetal fibroblasts, which normally lack telomerase, the enzyme that rebuilds the protective caps on chromosome ends (telomeres). The authors reported telomerase activity and longer telomeres. The abstract gives no sample numbers.
Human cells, 2025 (T4). A group at Brunel University London, outside the Russian network, reported longer telomeres in normal human cells and, through a mechanism some cancer cells use, in two breast-cancer cell lines. A correction in November 2025 replaced three of its figures. Cell results are not evidence of an effect in people.
Animals (T3). In older female rhesus monkeys, a study summarised by FDA staff reported higher evening melatonin and lower evening cortisol after epitalon; it did not measure sleep, and FDA staff call the functional relevance “unknown”. In a dish, epitalon did not increase melatonin release from rat pineal glands. A 2003 study followed female mice, 54 per group, until natural death; the authors reported no effect on body weight, average lifespan or total spontaneous tumours, and differences in some other measures. FDA staff write that, with one fixed amount, female mice only and short exposure, the group’s mouse studies “do not adequately inform” its cancer potential.
People (T2). FDA staff found three studies that gave epitalon to people. The one they describe in detail, from 2021, randomised 40 women aged 40 to 50, mostly night-shift workers with low urine levels of a melatonin breakdown product, to the peptide or placebo. Levels rose about 1.7-fold with the peptide and did not change on placebo. Blinding was not specified, the study was small and short, it did not measure sleep, and it reported no safety data, FDA staff note.
Registered, no results. One ClinicalTrials.gov record names epitalon (searched 18 Nov 2026): NCT07888595, an early phase 1, single-group study planned for 48 adults, testing a five-peptide skin serum alongside other agents. It is enrolling by invitation and has no results.
04What have regulators said about epithalon safety?
FDA staff found no published clinical study assessing epitalon’s safety, and two US documents read that gap differently.
FDA. FDA’s compounding page says epitalon products “may pose risk for immunogenicity for certain routes of administration”, that FDA “has not identified safety-related information regarding epitalon for the proposed route of administration”, and that it “lacks sufficient information to know whether the drug would cause harm if administered to humans”. FDA staff found no reports in FAERS, FDA’s adverse-event database, through 8 December 2025, no clinical studies assessing safety, and no two-year cancer studies in animals. They concluded that “there are no clinical data to support the safety” of epitalon in humans.
They added a theoretical concern. Epitalon has been reported to activate telomerase and lengthen telomeres, and longer telomeres are “generally associated with increased risk for cancer”, so “from the mechanistic standpoint, epitalon has the potential to be carcinogenic”. FDA staff found no study adequate to test it: there is no two-year cancer study, and they call the group’s mouse studies too limited.
HHS. HHS’s 2026 policy appendix calls CDER’s safety concerns “mechanistic rather than based on observed harm” and says “the limited controlled human exposure reported no side effects”. FDA staff describe a 2007 abstract that reported “no side effects” in older people, for epitalon and epithalamin together, as giving no details of how many people were studied, for how long, or how safety was checked; the 2021 randomised study reported no safety data. More: side effects, documented vs unknown.
05Is epithalon an approved medicine? Status by country
United States. Epitalon is not an FDA-approved drug or a component of one. HHS records that it sat in FDA’s compounding Category 2 from 29 September 2023 to 22 April 2026, that CDER recommended against listing either form, and that FDA’s compounding advisory committee voted in favour. For insomnia, the one nominated use they could evaluate, FDA staff found “a lack of evidence to support the effectiveness” of either form. HHS then named epitalon among six peptides in a policy saying it does not intend to pursue enforcement against state-licensed pharmacies, federal facilities and licensed physicians compounding with them, under conditions that include a patient-specific prescription. The Federal Register notice of 30 October 2026 calls the policy a draft that “is not binding”. It is not an approval. Background: the July 2026 vote, the HHS policy, FDA’s categories.
United Kingdom and Europe. FDA’s 2026 review found no approved product containing epitalon in the UK or seven other European countries, none authorised by the European Medicines Agency, and no entry in the European or Japanese Pharmacopoeia. More: are peptides legal in the UK?
Australia. Epitalon is not named in the Poisons Standard October 2026, and we found no group entry that would cover it; FDA’s review found no approved product in Australia. More: are peptides legal in Australia?
Sport. Epitalon is not named on WADA’s 2026 or 2027 Prohibited List. Class S0 prohibits at all times any substance not addressed elsewhere on the List “and with no current approval by any governmental regulatory health authority for human therapeutic use”. We know of no such approval for epitalon. See peptides and anti-doping.
06What doesn’t epithalon research show?
- Any effect on ageing or lifespan in people. No study we have reviewed shows one: see longevity research.
- Any effect on sleep. FDA staff found no study in people with insomnia, and no animal study that measured sleep.
- Its safety in people, short or long term, including the cancer question raised by the telomere findings.
- How far the findings hold outside one research group, the source of most pharmacological studies.
- What a vial sold online as epithalon contains. Only a lab report on that vial’s own lot can show it, and only for what the lab tested.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.